TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7178

Group type: COMPARATOR
Intervention: Thioridazine 10 mg t.i.d. (first week) and 20 mg t.i.d. (second week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bromazepam 6 mg t.i.d. during two weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bromazepam combined with alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (combined with bromazepam)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink (combined with thioridazine)
Number of subjects: 20
Study: 30584116

Group type: EXPERIMENTAL
Intervention: Rigid tape applied for 2 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 37
Study: 29097357

Group type: EXPERIMENTAL
Intervention: SPARX‐R (gamified online cognitive behavior therapy intervention)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 540
Study: 25322475

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Concentric exercise
Number of subjects: 11
Study: 23013104

Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Website
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Patient-based tutorial
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Handout
Number of subjects: 154
Study: 22164809

Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Yoga as exercise
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study: 19639376

Group type: EXPERIMENTAL
Intervention: 80% supplemental intraoperative oxygen
Number of subjects: 304

Group type: COMPARATOR
Intervention: Routine 30% oxygen (control)
Number of subjects: 304
Study: 16424411

Group type: EXPERIMENTAL
Intervention: Fish oil diet (3.2 g eicosapentaenoic acid and 2.0 g docohexaenoic acid)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fish oil diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 16
Study: 15227625

Group type: EXPERIMENTAL
Intervention: High-dose alanyl-glutamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (isonitrogenous glycine)
Number of subjects: 0
Study: 11063148

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg/h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 9060533

Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg/d for 2 weeks followed by 10 weeks of no drug, repeated for 8 cycles)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 8339412

Group type: EXPERIMENTAL
Intervention: Oral administration of 1200 mg bamiphylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bamiphylline (5 mg/kg in 15 minutes)
Number of subjects: 18
Study: 3333290

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 31477194

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 100
Study: 30158004

Group type: EXPERIMENTAL
Intervention: Brochure supplemented with phone‐based in‐depth messaging
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Brochure containing information on risks, benefits, and costs associated with lung cancer screening
Number of subjects: 1000
Study: 27391493

Group type: EXPERIMENTAL
Intervention: Immediately loaded tapered implants in postextraction sockets
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Immediately loaded tapered implants in healed sites
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both groups (postextraction sockets and healed sites)
Number of subjects: 39
Study: 25079049

Group type: EXPERIMENTAL
Intervention: Sonothrombolysis (transcranial Doppler monitoring plus intravenous tissue plasminogen activator)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator alone
Number of subjects: 85
Study: 23156967

Group type: EXPERIMENTAL
Intervention: Low level laser therapy with energy dose of 52.5 J/cm2 (G-I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low level laser therapy with energy dose of 105.0 J/cm2 (G-II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (0 J/cm2) (G-III)
Number of subjects: 45
Study: 21171265

Group type: COMPARATOR
Intervention: Doxazosin (4 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg/d) plus Doxazosin (4 mg/d)
Number of subjects: 64
Study: 18930104

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 52
Study: 15970833

Group type: EXPERIMENTAL
Intervention: Cefazolin given at skin incision (group A)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Cefazolin given at cord clamping (group B)
Number of subjects: 303
Study: 12907898

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 101
Study: 10486696

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study: 8759578

Group type: EXPERIMENTAL
Intervention: IV ketorolac 60 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination of IV ketorolac 60 mg and meperidine 50 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: IV meperidine 50 mg
Number of subjects: 154
Study: 1747501

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once a day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ranitidine (300 mg once a day)
Number of subjects: 43
Study: 7052040

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Combined cyclophosphamide and cis-diamminedichloroplatinum (cis DDP)
Number of subjects: 37
Study: 31792640

Group type: EXPERIMENTAL
Intervention: Dotinurad 0.5 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 30806926

Group type: EXPERIMENTAL
Intervention: Straw returning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feeding of forage
Number of subjects: 0

Group type: COMPARATOR
Intervention: RC treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: RC model
Number of subjects: 0
Study: 29122126

Group type: EXPERIMENTAL
Intervention: Direct reduction via a posterolateral approach and posteroanterior (PA) fixation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Indirect reduction and anteroposterior (AP) fixation
Number of subjects: 48
Study: 25881835

Group type: EXPERIMENTAL
Intervention: Jumbo forceps polypectomy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard forceps polypectomy
Number of subjects: 212
Study: 23812093

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment program (9 sessions)
Number of subjects: 70
Study: 21558576

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) solution 140 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) 140 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) capsules (low doses)
Number of subjects: 0
Study: 19655666

Group type: EXPERIMENTAL
Intervention: RAD1
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: RAD2
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation and association tests
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cronbach's Alpha
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Standard criterion vs scale
Number of subjects: 246
Study: 16728521

Group type: EXPERIMENTAL
Intervention: High peak SBP group (peak SBP > 210 mmHg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low peak SBP group (peak SBP ≤ 210 mmHg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 14982543

Group type: EXPERIMENTAL
Intervention: Educational interventions for practitioners in training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Practice-based interventions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of practice-based and educational interventions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Interventions (general)
Number of subjects: 24
Study: 11303007

Group type: EXPERIMENTAL
Intervention: Omacor 2 g twice a day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9231969

Group type: EXPERIMENTAL
Intervention: Dynamic strength back muscle training at a fitness center for the first 3 months, followed by a home training program
Number of subjects: 74

Group type: COMPARATOR
Intervention: Home training program for the first 3 months, followed by continued home training
Number of subjects: 74
Study: 8518552

Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon-alpha 2a
Number of subjects: 170

Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 170
Study: 3101790

Group type: EXPERIMENTAL
Intervention: Trial spatula
Number of subjects: 17000
Study: 29310613

Group type: EXPERIMENTAL
Intervention: Telephone outcall program (n = 108)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Attention control group (n = 108)
Number of subjects: 216
Study: 26447752

Group type: EXPERIMENTAL
Intervention: Aloe Vera Gel (AV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 60
Study: 26280589

Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment + Contingency Management (CBT + CM)
Number of subjects: 147
Study: 23052606

Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 186

Group type: COMPARATOR
Intervention: PD patients
Number of subjects: 186
Study: 21965360

Group type: EXPERIMENTAL
Intervention: Flexed 45 degrees at the thigh and maintained in that position for 15 minutes (group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Distal tourniquet applied with the leg in a neutral position during injection (group 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neutral position of the leg immediately after the patient was turned supine (group 1)
Number of subjects: 90
Study: 18385595

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Morphine PCA without Naloxone)
Number of subjects: 0
Study: 16826026

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) supplementation (2 g of L-carnitine per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-resistance exercise (RE) feeding (8 kcal/kg body mass: 56% carbohydrate, 16% protein, 28% fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feeding trials
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) supplementation
Number of subjects: 10
Study: 14520724

Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10802363

Group type: EXPERIMENTAL
Intervention: 35 Gy in 10 fractions
Number of subjects: 500

Group type: COMPARATOR
Intervention: 21 Gy in 3 fractions
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 500
Study: 8639131

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ambi hip screw
Number of subjects: 69
Study: 1483879

Group type: EXPERIMENTAL
Intervention: 2 mL hyperbaric tetracaine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 3 mL hyperbaric tetracaine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 4 mL hyperbaric tetracaine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.2 mg epinephrine added to anesthetic solution
Number of subjects: 102
Study: 3883701

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30725192

Group type: EXPERIMENTAL
Intervention: LHB tenodesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: LHB tenotomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 30663967

Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation (AMPS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: AMPS SHAM (placebo)
Number of subjects: 33
Study: 27260638

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 54
Study: 24336297

Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg, three injections in monthly intervals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Triamcinolone (8 mg, single injection followed by two sham interventions)
Number of subjects: 30
Study: 22314524

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q12h
Number of subjects: 797

Group type: COMPARATOR
Intervention: Vancomycin 1 g plus Aztreonam 1 g (V/A) q12h
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 797
Study: 20225989

Group type: EXPERIMENTAL
Intervention: Psychoprophylaxis during labor
Number of subjects: 857
Study: 17987533

Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy using hexaminolevulinate (HAL, Hexvix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cystoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy of bladder cancer
Number of subjects: 0
Study: 15714287

Group type: EXPERIMENTAL
Intervention: Bilateral leg strength training programme (6 weeks, three times per week)
Number of subjects: 33
Study: 12173299

Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diphtheria toxoid vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proliferative response to KLH and SWM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interferon-gamma and interleukin-13 release
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antigen-presenting cell-T-cell interaction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Booster immunization
Number of subjects: 40
Study: 10463407

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with continuous curvilinear capsulorhexis (group I)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction with linear capsulotomy (group II)
Number of subjects: 35
Study: 8747154

Group type: EXPERIMENTAL
Intervention: Speech-evoked FFRs from high- and low-probability words
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Category cues with word stimuli
Number of subjects: 80
Study: 2651744

Group type: EXPERIMENTAL
Intervention: Nutritional formula providing 20% protein, 30% fat, and 50% carbohydrate, 1 Kcal/ml, 400 ml/day for 13 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference product of the same consistency and taste containing 0.1 Kcal/ml, 400 ml/day for 13 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nutritional formula
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 28
Study: 1176233

Group type: EXPERIMENTAL
Intervention: Decreasing dose (N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continued methadone maintenance (N = 12)
Number of subjects: 24
Study: 29952075

Group type: EXPERIMENTAL
Intervention: In situ photo‐immunotherapy (ISPI) with 808 nm laser irradiation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical imiquimod alone
Number of subjects: 70
Study: 28068786

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid 20 mg/kg after sternotomy and 20 mg/kg after heparin reversal (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intrapericardial tranexamic acid 50 mg/kg in 20 mL of saline before sternal closure (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of intravenous tranexamic acid 20 mg/kg after sternotomy and intrapericardial tranexamic acid 50 mg/kg before sternal closure (Group C)
Number of subjects: 75
Study: 25700103

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Concurrent Training (BFR-CT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 25
Study: 23483571

Group type: EXPERIMENTAL
Intervention: 12.5 mg carvedilol tablets
Number of subjects: 34
Study: 21857020

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 50
Study: 19453736

Group type: EXPERIMENTAL
Intervention: Emollient used as maintenance therapy after topical corticotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical corticosteroid therapy
Number of subjects: 0
Study: 17101936

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 18411

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18411

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 18411

Group type: COMPARATOR
Intervention: Lisinopril vs Chlorthalidone
Number of subjects: 18411

Group type: COMPARATOR
Intervention: Amlodipine vs Chlorthalidone
Number of subjects: 18411
Study: 15610929

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 384
Study: 12352270

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Fluoxetine 40 mg alone (medication management)
Number of subjects: 132
Study: 9924849

Group type: EXPERIMENTAL
Intervention: Carvedilol (target dose 25 mg twice daily)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 7636712

Group type: EXPERIMENTAL
Intervention: Upper mid-arm circumference
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tape measure nomogram
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Guessing
Number of subjects: 37
Study: 2616824

Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol via Rotacaps
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol via Rotacaps
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol via Rotacaps
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol via nebulizer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol via nebulizer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol via nebulizer
Number of subjects: 18
Study: 326295

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol (800 microgram per day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30879186

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SITG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent training (CTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training (RTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All interventions (RTG, SITG, CTG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CONG)
Number of subjects: 30
Study: 28650683

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no mechanical bowel preparation)
Number of subjects: 102
Study: 25552372

Group type: EXPERIMENTAL
Intervention: Reduced glycogen (RED)
Number of subjects: 12
Study: 23715097

Group type: EXPERIMENTAL
Intervention: Right primary auditory cortex to right superior temporal gyrus (feed-forward) connection modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left primary auditory cortex to right primary auditory cortex (interhemispheric) connection modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left superior temporal gyrus to right superior temporal gyrus connection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right superior temporal gyrus to right primary auditory cortex connection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-connections in left primary auditory cortex and bilateral superior temporal gyrus
Number of subjects: 0
Study: 21849054

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 268
Study: 19101251

Group type: EXPERIMENTAL
Intervention: Immersive virtual patient (VP) interaction
Number of subjects: 21

Group type: COMPARATOR
Intervention: No VP interaction (control)
Number of subjects: 21
Study: 17353778

Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 216

Group type: COMPARATOR
Intervention: Aza
Number of subjects: 216
Study: 14756852

Group type: EXPERIMENTAL
Intervention: Sumatriptan formulations (various routes of administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo formulations (matching sumatriptan formulations)
Number of subjects: 0
Study: 11445210

Group type: EXPERIMENTAL
Intervention: Group 1: One Step applied with the small brush provided by the manufacturer and LC (Light‐cured before resin cement application)+Dual Link resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 2: One Step applied with a thin microbrush LC+Dual Link resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 3: One Step applied with a small brush (Not light‐cured)+Dual Link resin cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 4: All Bond 2+C & B resin cement (as control)
Number of subjects: 40
Study: 9692690

Group type: EXPERIMENTAL
Intervention: Sodium alginate (4 sachets per day)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cisapride (5 mg four times a day)
Number of subjects: 353